Development of a Novel, Non-Invasive Diagnostic Test for Prostate Cancer
Abstract
To examine ejaculate in the diagnosis of prostate cancer, initially we confirmed that seminal fluid was comparable with prostatic fluid collected in urine following prostatic massage as a source for analysis for expression of the non-coding RNA PCA3 in relation to PSA RNA. For a total of 158 cases, we identified a sensitivity of 63%, a specificity of 72.5% (94% negative predictive value). Based on extensive molecular profiling of malignant and benign prostatic tissue in which a combination of 3 highly-discriminating markers detected 100% of cancers, we examined these in ejaculate and post-ejaculate urines. Results were then analysed in conjunction with serum prostate specific antigen (PSA) levels, clinically the primary indication for diagnostic biopsies currently. Our best results were obtained using a combination of ejaculate PSA and hepsin in conjunction with serum PSA which provided an 82% sensitivity and a 92% specificity for a negative predictability of 89% for 44 patients. The study is ongoing.
Document Details
- Document Type
- Technical Report
- Publication Date
- Jan 01, 2008
- Accession Number
- ADA499854
Entities
People
- Martin F Lavin
- Robert A. Gardiner
Organizations
- University of Queensland